Alnylam Pharmaceuticals stock gets a Strong Buy upgrade from Zacks Research

Published on 10/08/2026 at 06:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alnylam Pharmaceuticals stock received a Strong Buy upgrade from Zacks Research as of October 7, 2026. Q2 revenue rose 74 percent to USD 1.2 billion.

Alnylam Pharmaceuticals, US02043Q1076, Illustration mit AI erstellt.

Alnylam Pharmaceuticals stock (ISIN US02043Q1076) was trading at USD 225.57 on Nasdaq on October 7, 2026, at 2:11 p.m. EDT, up 0.73 percent from the previous close. The latest analyst action came from Zacks Research, which upgraded the shares to Strong Buy from Hold, MarketBeat reported.

Zacks upgrade meets a divided market

The upgrade contrasts with a share price still 54.5 percent below the 52-week high of USD 495.55 and USD 27.76 above the 52-week low of USD 197.81, both recorded on the October 7 quote. The session range was USD 222.46 to USD 230.42, while trading volume reached 444,485 shares.

The same MarketBeat report lists 3 Strong Buy, 16 Buy and 6 Hold ratings, producing a Moderate Buy consensus across 25 analysts. Its average price target is USD 366.90, which stands 62.7 percent above the October 7 price.

Q2 growth carries the operating case

Alnylam's latest operating figures provide the numerical reason for the bullish view. Q2 2026 net product revenue increased 74 percent year over year to USD 1.2 billion, led by AMVUTTRA and the wider TTR franchise, according to Stock Analysis.

The company had also adjusted 2026 TTR franchise guidance to USD 4.2 billion to USD 4.5 billion, a USD 200 million reduction at the midpoint, as demand patterns normalized. That combination leaves investors weighing rapid revenue expansion against a lower near-term outlook for the flagship franchise.

JPMorgan trims target to USD 369

Analyst views remain mixed beneath the latest upgrade. Yahoo Finance lists JPMorgan maintaining an Overweight rating while lowering its price target from USD 375 to USD 369 on September 30, 2026, reflecting revised AMVUTTRA estimates, Yahoo Finance reports.

Stock remains below its yearly high

Alnylam Pharmaceuticals stock was last quoted at USD 225.57 on Nasdaq on October 7, 2026, at 2:11 p.m. EDT. Its USD 30.2 billion market capitalization and the 54.5 percent gap to the 52-week high put the analyst upgrade beside a still demanding valuation debate.